Clinical Trials Directory

Trials / Completed

CompletedNCT01858155

Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
9 (actual)
Sponsor
C17 Council · Academic / Other
Sex
All
Age
2 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate dose escalation of melatonin in pediatric oncology patients with relapsed solid tumors. The purpose of this study is to determine the safety of melatonin at a dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.

Conditions

Interventions

TypeNameDescription
DRUGMelatonin

Timeline

Start date
2013-05-01
Primary completion
2017-12-01
Completion
2017-12-31
First posted
2013-05-21
Last updated
2019-01-31

Locations

5 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01858155. Inclusion in this directory is not an endorsement.